# Avisi Technologies

> Avisi Technologies is a clinical-stage ophthalmic medical device company building VisiPlate, an ultrathin, nanotechnology-enabled aqueous shunt that drains excess fluid from the eye to lower pressure in glaucoma patients. Spun out of the University of Pennsylvania's Y-Prize program in 2017, the company is advancing VisiPlate through the FDA-cleared SAPPHIRE pivotal trial and has raised roughly $21.7M to date, including a $10.7M Series A in February 2026.

- **Founded:** 2017
- **Headquarters:** Redwood City, California, United States
- **Founders:** Rui Jing Jiang (Co-Founder, CEO & Director), Brandon Kao (Co-Founder, MD)
- **Team size:** ~19 employees
- **Products:** VisiPlate, VisiPlate-S, V-001
- **Notable:** Spun out of the University of Pennsylvania Y-Prize program and won the President's Innovation Prize (2017-2018)., Received FDA Investigational Device Exemption (IDE) approval for the SAPPHIRE pivotal trial in 2025., Implanted its first patient with VisiPlate in the SAPPHIRE trial.

## Products & services

- **VisiPlate** — An ultrathin, nanotechnology-enabled aqueous shunt - roughly 20x thinner than a human hair - that continuously drains excess fluid from the eye through multiple redundant microchannels to lower intraocular pressure. Built from biocompatible alumina and Parylene-C to minimize scarring and foreign-body response. Flagship device in the SAPPHIRE pivotal trial.
- **VisiPlate-S** — A drainage device variant designed to treat mild-to-moderate glaucoma at the time of cataract surgery.
- **V-001** — A sustained intraocular drug-delivery platform extending Avisi's glaucoma pipeline beyond mechanical drainage.

## Achievements

- Spun out of the University of Pennsylvania Y-Prize program and won the President's Innovation Prize (2017-2018).
- Received FDA Investigational Device Exemption (IDE) approval for the SAPPHIRE pivotal trial in 2025.
- Implanted its first patient with VisiPlate in the SAPPHIRE trial.
- Won the Glaucoma Foundation's H. Dunbar Hoskins International Innovation Award.
- Won the Octane Ophthalmology Technology Summit People's Choice Award.
- Co-founder Rui Jing Jiang named one of Greater Philadelphia's Inno Under 25.
- Raised approximately $21.7M in total funding across grants and venture rounds.

## Latest updates

- **2026-02** — Closed a $10.7M Series A led by MedVenture Partners to fund the SAPPHIRE pivotal trial and broader glaucoma pipeline.
- **2025** — Received FDA IDE approval and began enrolling the SAPPHIRE pivotal trial; first patient implanted with VisiPlate.

## Links

- Website: https://avisitech.com
- LinkedIn: http://www.linkedin.com/company/avisi-technologies
- Twitter/X: https://twitter.com/avisi_tech
- Facebook: https://facebook.com/avisitech

---

Profile page: https://yespress.io/avisi-technologies
Published by YesPress — https://yespress.io
Last updated: 2026-06-16